Mice Model Market Overview
The Mice Model Market is expanding as pharmaceutical companies, biotechnology firms, and research institutions increasingly rely on advanced animal models for drug discovery, disease research, genetic studies, and personalized medicine. Advancements in genetic engineering, rising demand for precise preclinical models, increasing biomedical research investment, and growing cancer research activity are supporting market growth.
According to the Market Research Future report updated August 27, 2026, the global Mice Model Market was valued at USD 1.677 Billion in 2024 and is projected to grow from USD 1.781 Billion in 2025 to USD 3.251 Billion by 2035, registering a CAGR of 6.2% during 2025–2035. North America leads the market with approximately 45% share, while Asia-Pacific is the fastest-growing region. Genetically Engineered Mice represent the dominant model type, Breeding is the largest service segment, CRISPR/CAS9 is the leading technology, Oncology is the largest therapeutic area, and Drug Discovery & Development is the dominant application segment.
Unlock Exclusive Insights – Request Your Free Sample Report Now!
https://www.marketresearchfuture.com/reports/mice-model-market-21972
Key players driving innovation and competitiveness in the Mice Model Market include:
Charles River Laboratories
The Jackson Laboratory
Taconic Biosciences
Envigo
Harlan Laboratories
Crown Bioscience
Janvier Labs
InVivo Biosystems
GenOway
The market is being shaped by advancements in genetic engineering, increasing demand for personalized medicine, rising investment in biomedical research, and the growing need for accurate preclinical models. CRISPR/CAS9 and other gene-editing technologies are enabling researchers to develop precise disease models, while alternative approaches such as humanized mice and organoids are gaining attention. Increasing drug discovery activity and cancer research are also supporting demand for specialized mice models.
The Mice Model Market can be segmented by Model Type into Inbred Mice, Genetically Engineered Mice, Hybrid/Congenic Mice, and Outbred Mice. By Service, it includes Breeding, Cryopreservation, Rederivation, Quarantine, and Other Services. By Technology, it covers CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer, and Other Technologies. By Therapeutic Area, it includes Oncology, Metabolic Diseases, Immunology, Neurology, Cardiovascular Diseases, and Other Therapeutic Diseases. By Application, it covers Drug Discovery & Development, Research Application, and Personalized Medicine. By End User, it includes Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, and CROs & CDMOs.
The growing need for sophisticated preclinical research models is creating opportunities for mouse-model providers, biotechnology companies, pharmaceutical manufacturers, academic institutions, and contract research organizations. Genetically modified models for specific diseases, expanded CRO services, personalized medicine research, advanced gene-editing technologies, and AI-supported research analytics can provide significant opportunities for market participants.
Recent Developments and Market Trends:
Advancements in genetic engineering are enabling the development of increasingly precise mouse models that better replicate human diseases and support translational research.
CRISPR/CAS9 is strengthening its position as a leading technology by enabling efficient knockout and knock-in models for genetic disease research and therapeutic development.
Personalized medicine is increasing demand for models that reflect individual genetic variations and specific disease characteristics.
Alternative research approaches, including humanized mice and organoids, are gaining attention as researchers seek models that provide more relevant insights into human biology.
AI integration, digitalization, sustainability initiatives, and strategic partnerships are increasingly influencing competitive differentiation among mice model providers.
Reasons to Buy the Report:
Provides comprehensive insights into the Mice Model Market dynamics, trends, opportunities, and growth potential.
Helps identify opportunities across genetically engineered mice, inbred mice, breeding, cryopreservation, CRISPR/CAS9, and other key categories.
Offers detailed segmentation analysis across model type, service, technology, therapeutic area, application, end user, and geographic markets.
Includes competitive intelligence covering leading mice-model providers and research organizations.
Supports strategic decisions using market forecasts, genetic-engineering advancements, drug-discovery demand, personalized-medicine trends, biomedical research investment, and regional opportunities.
Future Outlook:
The future of the Mice Model Market will be shaped by advancements in genetic engineering, increasing demand for personalized medicine, growing pharmaceutical R&D, and rising investment in biomedical research. Genetically Engineered Mice should remain the dominant model type, while Inbred Mice are expected to record strong growth because of their consistent genetic backgrounds and reproducibility. Breeding should continue to lead the service segment, with Cryopreservation gaining importance as demand for long-term preservation of genetic material increases. CRISPR/CAS9 is expected to remain the leading technology, while Microinjection offers strong growth potential. Oncology should retain its position as the largest therapeutic area, supported by extensive cancer research, while Immunology is emerging rapidly. Drug Discovery & Development should remain the largest application, although Personalized Medicine is positioned for significant growth. Pharmaceutical & Biotechnology Companies will remain the largest end-user group, while Academic & Research Institutes are expected to grow rapidly. North America should retain market leadership at approximately 45% share, while Asia-Pacific is expected to remain the fastest-growing region. Market Research Future projects the Mice Model Market to reach USD 3.251 Billion by 2035 at a CAGR of 6.2% during 2025–2035.
➤➤Explore Our Latest Related Reports:
